AMGN
T2Amgen Inc.
OverviewAmgen Inc. discovers, develops, manufactures, and delivers human therapeutics globally, focusing on inflammation, oncology, bone health, cardiovascular, nephrol
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics globally, focusing on inflammation, oncology, bone health, cardiovascular, nephrology, and neuroscience. Key products like Repatha, Evenity, and TestSpire are strong growth drivers. The company also has a significant biosimilars portfolio and a promising pipeline, including Meritide for obesity. It serves healthcare providers and is expanding direct-to-patient access.
- What They Do (Plain English & Analogies)
- Amgen is like a specialized farm that grows unique, powerful medicines to help people with serious illnesses. Instead of growing crops, they "grow" complex biological drugs, often made from living cells, to target specific problems in the body. They focus on areas like cancer, heart disease, bone problems, and rare conditions where existing treatments aren't good enough. They discover these new medicines, test them rigorously to make sure they're safe and effective, manufacture them in large quantities, and then get them to doctors and patients around the world. They also make "generic" versions of complex biological drugs (called biosimilars) which are like high-quality, more affordable copies of existing brand-name biological medicines, making important treatments accessible to more people.
- Very Brief History
- Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California. Over the decades, it has grown into a leading biotechnology company, focusing on discovering, developing, manufacturing, and delivering human therapeutics across various therapeutic areas. Key milestones include the launch of numerous blockbuster drugs and a continuous investment in a robust pipeline, including innovative therapies and biosimilars. The company has expanded its global reach and continues to evolve through strategic collaborations and significant R&D investments.
- "Street Stereotype"
- Amgen is generally perceived by investors and analysts as a mature, large-cap biotechnology company with a strong, diversified portfolio of established blockbuster drugs and a significant presence in biosimilars, providing stable cash flow. However, it's also seen as a company with a promising late-stage pipeline, particularly in high-growth areas like obesity (with Meritide) and cardiovascular disease, which could drive future growth. There's also an awareness of the ongoing challenge of biosimilar competition for some of its older, high-revenue products, requiring continuous innovation and pipeline success to offset potential erosion.
- Subsidiaries On Linked In*
- {"subsidiaries":[]}
- Customer Sectors & Example Clients
- Amgen serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. Based on their business model and industry, example clients would include large healthcare systems (e.g., Kaiser Permanente), pharmacy benefit managers (e.g., CVS Health, Express Scripts), and various hospital networks.
- New Customers / Segments They'Re Targeting
- Amgen is actively targeting several new customer segments and expanding into new markets. With Meritide, they are aiming to reach millions of patients with obesity, type 2 diabetes, and obesity-related conditions like sleep apnea, offering a differentiated, less frequent dosing option. Repatha's new data from the Vesalius CV trial allows them to target high-risk patients who have not yet had a heart attack or stroke, expanding beyond secondary prevention. They are working to update clinical guidelines to encourage cardiologists and primary care physicians to manage LDL cholesterol more proactively in this population. Uplisna has recently received approvals for IgG4-related disease and generalized myasthenia gravis, opening up new patient populations, and they are advancing Uplisna for autoimmune hepatitis and chronic inflammatory demyelinating polyneuropathy (CIDP). Tepezza is expanding its reach to patients with lower clinical activity score Thyroid Eye Disease (TED), who are often managed by different specialists like endocrinologists. Additionally, they plan to launch TEPEZZA in additional international markets in 2026, expanding access to this important therapy globally.
- Supply Chain And Sourcing Geographies
- Amgen's supply chain involves significant manufacturing operations within the United States and Puerto Rico. The company has made substantial capital expenditures in 2025 and plans for 2026 to support continued volume growth in its commercial brands and prepare for pipeline product launches, including Meritide. Specific locations mentioned for these investments include Ohio, North Carolina, Puerto Rico, Rhode Island, and California.
- Sales Geographies And Expansion Plans
- Amgen currently sells its products worldwide. Specific geographies mentioned in the transcript include the U.S. and Japan. The company is also expanding access to Tepezza by planning launches in additional international markets in 2026. The EU is mentioned in the context of generic launches for Otezla.
- How Key Themes May Help/Hurt
- The 'MedTech Short '25: Heavy China Exposure' theme could potentially hurt Amgen if the ongoing hostility toward China-linked biopharma operations intensifies, leading to supply chain restructuring costs, increased regulatory scrutiny, or shifts in procurement preferences, although the transcript does not detail Amgen's specific revenue exposure to China. The 'GLP-1 Long '24: GLP1 Drug Producer' theme is highly beneficial for Amgen. The company is actively developing Meritide, a late-stage therapy for obesity, type 2 diabetes, and obesity-related conditions, directly aligning with the bullish thesis for GLP-1 drugs. Meritide's potential for infrequent dosing (monthly, every other month, or quarterly) could be a significant differentiator in this growing market, enhancing patient compliance and persistence. Amgen's internal pipeline also includes other obesity assets, further strengthening its position in this high-growth area.
3 Main Long-Term Bull Details
- Amgen possesses a robust and differentiated late-stage pipeline, including Meritide for obesity and type 2 diabetes, opaziran for cardiovascular disease, and expanded indications for Uplisna, which are positioned to address large unmet medical needs and drive multi-billion dollar franchises for the rest of the decade.
- The company maintains a strong, diversified portfolio of growth brands, with 14 products achieving blockbuster status and 13 products showing double-digit growth in 2025, providing a stable revenue base that can offset biosimilar erosion on older products.
- Amgen is an industry leader in biosimilars, a business that generated $3 billion in sales in 2025 and provides durable cash flow and broad patient access, complemented by strategic investments in R&D and leveraging AI across the value chain for sustained innovation.
3 Main Long-Term Bear Details
- Amgen faces significant revenue erosion from increasing biosimilar competition for key products like Prolia and Enbrel, as well as anticipated impacts from denosumab biosimilars, necessitating continuous pipeline success to replace lost revenue.
- The inherent risks of drug development are evident in pipeline failures, such as the termination of rocatinlimab development and the decision not to pursue regulatory approval for bimirtuzumab, alongside regulatory challenges like the FDA's requested voluntary withdrawal of Tavneos.
- The company anticipates pricing pressures and market access challenges, including sales erosion for Otezla due to unfavorable U.S. pricing and generic launches in the EU, and broader industry trends like increased 340B program utilization.
- Competitors And Differentiation
- Amgen faces competition across its diverse portfolio. For PCSK9 inhibitors like Repatha, competitors include other PCSK9 inhibitors, and Amgen differentiates with comprehensive outcomes data for both high-risk primary and secondary prevention, positioning it as the most evidence-backed therapy in its class. In the obesity/type 2 diabetes market, Meritide aims to differentiate with its potential for strong efficacy, favorable tolerability, and paradigm-changing infrequent dosing (monthly, every other month, or even quarterly) against established GLP-1 receptor agonists. Evenity, for bone health, differentiates as the only treatment that simultaneously builds new bone and reduces bone resorption. Uplisna, in rare disease, stands out with its upstream CD19-directed B-cell mechanism, demonstrated safety profile, and convenient twice-yearly dosing. TestSpire differentiates in asthma through its TSLP mechanism targeting multiple inflammatory pathways. In oncology, Imdeltra has rapidly become the standard of care in second-line or later small cell lung cancer due to unprecedented survival benefits, and Blincyto is a standard of care in Philadelphia chromosome-negative b-cell ALL. As an industry leader in biosimilars, Amgen competes with innovator biologics and other biosimilar manufacturers, leveraging its manufacturing reliability and product features like ready-to-use prefilled syringes for Pav Blue.
- Recent Performance & What The Market'S Focused On
- Amgen delivered strong operational performance in 2025, achieving double-digit growth in revenues and earnings per share, with 14 products reaching blockbuster status and 18 achieving record sales. For 2026, the company expects total revenues between $37 billion and $38.4 billion and non-GAAP EPS between $21.6 and $23, driven by key growth brands offsetting anticipated declines from biosimilar competition and pricing pressures. The market is primarily focused on the development and potential of Meritide, Amgen's obesity and type 2 diabetes drug, particularly its differentiated dosing schedule. The impact of biosimilar competition on products like Prolia and Enbrel, and how new growth drivers will offset these declines, is also a key focus. Additionally, investors are tracking Repatha's growth and market expansion following the Vesalius CV trial data, and overall pipeline execution and regulatory outcomes.
- Revenue Segments And Estimated Mix
- Innovative Oncology Portfolio — Mix: ~23% (based on $8.7B of $37-38.4B total revenue guidance); Source: 2025 full-year sales were $8.7 billion.; Trend: Grew 11% year over year in 2025.
- Rare Disease Portfolio — Mix: ~14% (based on $5.2B of $37-38.4B total revenue guidance); Source: 2025 full-year sales were nearly $5.2 billion.; Trend: Grew 14% year over year in 2025.
- Biosimilars Portfolio — Mix: ~8% (based on $3B of $37-38.4B total revenue guidance); Source: 2025 full-year sales were $3 billion.; Trend: Increased 37% to $3 billion in 2025.
- Repatha — Mix: ~8% (based on $3B of $37-38.4B total revenue guidance); Source: 2025 sales surpassed $3 billion.; Trend: Grew 36% year over year in 2025.
- Prolia — Mix: ~12% (based on $4.4B of $37-38.4B total revenue guidance); Source: 2025 sales were $4.4 billion.; Trend: Increased 1% year over year in 2025; accelerated sales erosion expected in 2026.
- Evenity — Mix: ~6% (based on $2.1B of $37-38.4B total revenue guidance); Source: 2025 sales reached $2.1 billion.; Trend: Increased 34% in 2025.
- Tepezza — Mix: ~5% (based on $1.9B of $37-38.4B total revenue guidance); Source: 2025 sales were $1.9 billion.; Trend: Grew 3% in 2025.
- TestSpire — Mix: ~4% (based on $1.5B of $37-38.4B total revenue guidance); Source: 2025 sales were nearly $1.5 billion.; Trend: Grew 52% year over year to nearly $1.5 billion for the full year.
- Otezla — Mix: ~6% (based on assumed $2.3B of $37-38.4B total revenue guidance); Source: 2025 sales increased 7% year over year to nearly $23 billion (assumed typo, likely $2.3 billion).; Trend: Increased 7% year over year in 2025; sales erosion expected in 2026.
- Blincyto — Mix: ~4% (based on $1.5B of $37-38.4B total revenue guidance); Source: 2025 full-year sales were over $1.5 billion.; Trend: Grew 28% year over year in 2025.
- Imdeltra — Mix: ~2% (based on $627M of $37-38.4B total revenue guidance); Source: 2025 full-year sales were $627 million.; Trend: Fueled by strong clinical conviction and rapid adoption.
- Uplisna — Mix: ~2% (based on $655M of $37-38.4B total revenue guidance); Source: 2025 sales increased 73% year over year to $655 million.; Trend: Increased 73% year over year in 2025.
- Pav Blue — Mix: ~2% (based on $700M of $37-38.4B total revenue guidance); Source: 2025 sales reached $700 million.; Trend: Continues to gain momentum.
- Tavneos — Mix: ~1% (based on $459M of $37-38.4B total revenue guidance); Source: 2025 sales were $459 million.; Trend: Increased 62% year over year in 2025.
- Product Brands
- Repatha
- Evenity
- TestSpire
- Uplisna
- Imdeltra
- Meritide
- Opaziran
- Prolia
- Tepezza
- Tavneos
- Otezla
- Blincyto
- Pav Blue
- Enbrel
- Neulasta
- Xgeva
- Aranesp
- KYPROLIS
- Nplate
- Vectibix
- MVASI
- Parsabiv
- EPOGEN
- KANJINTI
- Aimovig
- AMGEVITATM
- Sensipar/Mimpara
- NEUPOGEN
- IMLYGIC
- Corlanor
- AVSOLA
- ABP-206
- ABP-234
- Desodoliveb
- Daxdilimab
- Zalaritamab
- AMG 513
Bull / Bear DetailsAmgen Inc. demonstrates strong growth in key products like Repatha and Evenity, with a promising pipeline led by Meritide for obesity and diabetes. However, sig
Thesis
Amgen Inc. demonstrates strong growth in key products like Repatha and Evenity, with a promising pipeline led by Meritide for obesity and diabetes. However, significant headwinds from accelerated biosimilar competition for Prolia and Otezla, coupled with regulatory uncertainty for Tavneos, present material risks. The unaddressed implications of geopolitical tensions on China-linked operations further cloud the outlook, making the bear case slightly more compelling as of April 24, 2026.
Bull case
Amgen's diversified portfolio continues to deliver, with 14 products achieving blockbuster status and 13 showing double-digit sales growth in 2025. Key growth drivers like Repatha, Evenity, and TestSpire grew over 30% year-over-year, positioning them as significant contributors for the rest of the decade.
The late-stage pipeline, particularly Meritide, represents a potential paradigm shift in obesity and type 2 diabetes treatment. With strong efficacy and favorable tolerability at monthly, bimonthly, or even quarterly dosing, Meritide is advancing rapidly through six global Phase III studies, addressing a major unmet need.
Repatha's position as a leader in cardiovascular health is strengthened by landmark Vesalius CV trial data, demonstrating a 25% relative risk reduction in major cardiovascular events for high-risk patients. This data supports its role in both primary and secondary prevention, potentially leading to updated clinical guidelines and increased adoption.
Bear case
Amgen anticipates accelerated sales erosion for Prolia and Otezla in 2026 due to increased competition from multiple biosimilars and generic launches globally, alongside unfavorable U.S. pricing. This competitive pressure is expected to significantly offset growth from newer products.
Regulatory uncertainty surrounds Tavneos (avacopan) following the FDA's request for a voluntary withdrawal due to concerns about the readjudication of primary endpoint results for nine patients. This situation poses a risk to the product's market presence and could signal broader regulatory scrutiny.
Despite strong operational performance, Amgen's potential exposure to China-linked biopharma operations remains an unaddressed risk. The ongoing geopolitical hostility toward China-linked entities, as highlighted by the 'MedTech Short '25' theme, could lead to future supply chain disruptions or procurement shifts, impacting global revenue streams.
Bull / Bear Case
- Bear Case
- Amgen faces significant near-term headwinds, including anticipated accelerated sales erosion for Prolia and Otezla in 2026 due to increased competition from multiple biosimilars, generic launches, and unfavorable U.S. pricing. Regulatory uncertainty surrounds Tavneos (avacopan) following the FDA's request for a voluntary withdrawal due to concerns about primary endpoint readjudication, posing a risk to its market presence. Pipeline setbacks, such as the termination of rocotinlimab and the decision not to pursue bimirtuzumab, highlight inherent R&D risks. The company also expects seasonal Q1 2026 sales headwinds and lower operating margins. Furthermore, free cash flow growth has been negative in recent periods, and the stock's performance has underperformed the broader market since its post-earnings peak, reflecting investor caution amidst these challenges.
- Bull Case
- Amgen Inc. delivered strong operational performance in 2025, achieving double-digit revenue and EPS growth, with 14 products reaching blockbuster status and 18 achieving record sales. Key growth drivers like Repatha, Evenity, and TestSpire grew over 30% year-over-year and are expected to drive growth for the rest of the decade. The late-stage pipeline is robust, particularly Meritide for obesity and type 2 diabetes, which is rapidly advancing through six global Phase III studies and offers a potential paradigm shift with infrequent dosing. Repatha's leadership in cardiovascular health is further strengthened by landmark clinical data. The rare disease, innovative oncology, and biosimilars portfolios also demonstrate significant growth and future potential, supported by strategic investments in R&D and AI across the value chain. Management projects 2026 as a 'springboard year' for future growth, with strong revenue and EPS guidance.
- More Compelling & Why
- Bear Case. While Amgen's P/E ratio of approximately 24.6 is near its historical average, its EV/EBITDA of 14.03x is 14% above its 10-year median, and free cash flow growth has been negative. The most compelling bear argument is the anticipated accelerated sales erosion for key products like Prolia and Otezla due to increased biosimilar and generic competition, coupled with regulatory uncertainty surrounding Tavneos. This creates significant near-term headwinds that could pressure revenue and margins, despite pipeline potential. My view would flip to bullish if Amgen demonstrates stronger than expected resilience against biosimilar competition and provides clear, positive resolution on Tavneos's regulatory status, leading to upward revisions in FCF growth projections.
Key Factors
| Key Factor | Why It Matters | What To Watch | What It Signals | Where/How To Track | Free Alt Data | Paid Alt Data |
|---|---|---|---|---|---|---|
| Resolution of the FDA's request for voluntary withdrawal of Tavneos (avacopan) due to concerns about primary endpoint readjudication. | The FDA's request creates significant regulatory uncertainty. It could lead to a loss of revenue from Tavneos, impacting Amgen's rare disease portfolio and reputation. | Official communication from Amgen or the FDA regarding Tavneos's regulatory status, including a decision on withdrawal or a path forward. | Bearish: FDA mandates withdrawal of Tavneos, or Amgen voluntarily withdraws the product, leading to cessation of sales. | Amgen press releases, SEC filings (8-K), FDA announcements, and future earnings calls. | FDA website for drug approvals/withdrawals, pharmaceutical industry news. | |
| Accelerated sales erosion for Prolia due to increased denosumab biosimilar competition. | Prolia is a blockbuster product. Significant erosion from biosimilars directly impacts Amgen's top-line revenue and profitability, challenging its ability to offset declines with growth drivers. | Q1 2026 and subsequent quarterly sales figures for Prolia and Xgeva. Monitor year-over-year percentage change and absolute sales decline. | Bearish: Prolia sales decline exceeding management's 'accelerated sales erosion' expectations or significantly impacting overall 2026 revenue guidance. | Amgen's Q1 2026 earnings report (expected late April/early May 2026) and subsequent quarterly reports. | FDA biosimilar approval tracker for denosumab, news articles on biosimilar launches and market share. | IQVIA: Prescription volume and market share data for denosumab biosimilars vs. Prolia/Xgeva. |
| Amgen's actual Q1 2026 total revenues and non-GAAP operating margin compared to company guidance. | Q1 performance sets the tone for the year. Missing initial guidance indicates competitive pressures and headwinds are stronger than anticipated, undermining full-year projections. | Q1 2026 total revenues (guidance: lower mid-single-digit year-over-year growth) and non-GAAP operating margin (guidance: lowest of the year, roughly same as 2025). | Bearish: Q1 2026 total revenue growth below 'lower mid-single-digit' year-over-year, or Q1 non-GAAP operating margin significantly below 2025 Q1 levels. | Amgen's Q1 2026 earnings report (expected late April/early May 2026) and associated conference call transcript. | Financial news outlets (Reuters, Bloomberg) reporting on earnings estimates and actuals. | FactSet/Refinitiv: Consensus analyst estimates for Q1 revenue and EPS; Bloomberg Terminal: Real-time earnings tracking. |
| Delays in the Meritide Phase III program (ASCVD, heart failure, sleep apnea studies) or release of data that is not 'paradigm-changing' as expected. | Meritide is a major future growth driver. Setbacks in its extensive Phase III program (efficacy, tolerability, dosing) would significantly dampen future revenue expectations and investor sentiment. | Updates on enrollment completion, study completion dates, and initial data readouts for the six global Phase III studies. | Bearish: Announcement of significant delays in study completion/data readout, or preliminary data indicating lower-than-expected efficacy, worse tolerability, or inability to achieve less frequent dosing targets. | Amgen press releases, SEC filings, clinical trial registries (ClinicalTrials.gov), scientific conference presentations, and future earnings calls. | ClinicalTrials.gov: Status updates on Meritide (AMG 133) trials, scientific conference abstracts. | GlobalData/EvaluatePharma: Analyst consensus on trial timelines and probability of success; TrialScope: Detailed trial progress tracking. |
| Otezla sales erosion driven by unfavorable U.S. pricing and generic launches in the EU. | Otezla is a significant product. Sustained sales erosion due to pricing pressure and generic competition will negatively impact Amgen's revenue and ability to meet full-year financial targets. | Q1 2026 and subsequent quarterly sales figures for Otezla. Monitor year-over-year percentage change and absolute sales decline, particularly in the EU. | Bearish: Otezla sales decline exceeding expectations or if generic competition in the EU gains market share faster than anticipated. | Amgen's Q1 2026 earnings report (expected late April/early May 2026) and subsequent quarterly reports. | European Medicines Agency (EMA) generic approval databases, pharmaceutical news outlets reporting on generic launches and pricing. | IQVIA: Prescription volume and market share data for Otezla and its generic competitors in key EU markets. |
Key Reported Metrics
| Metric | Why It Matters | Last Period |
|---|---|---|
| Biosimilar Portfolio Sales | The biosimilar portfolio is a significant contributor to Amgen's revenue and cash flow, poised for future growth with new launches. Its performance demonstrates the company's competitive strength and ability to offset declines in other mature products. | 37% |
| Total Revenues | This metric reflects Amgen's overall financial performance and its ability to grow despite competitive pressures and product declines, indicating the effectiveness of its diversified portfolio and pipeline. Investors will monitor this for alignment with 2026 guidance. | 9% |
| Repatha Sales | Repatha is a key growth driver with strong clinical data for cardiovascular risk reduction. Its continued sales momentum is crucial for Amgen's top-line growth and market leadership in cardiometabolic diseases, especially with new data and expanded access programs. | 44% |
Key QuestionsWill the sales erosion for Prolia and Otezla due to increased biosimilar competition and unfavorable pricing in Q1 2026 and beyond exceed management's anticipat
Will the sales erosion for Prolia and Otezla due to increased biosimilar competition and unfavorable pricing in Q1 2026 and beyond exceed management's anticipated declines, impacting overall revenue guidance?
- Question 2
Will the ongoing Meritide Phase III program deliver 'paradigm-changing' efficacy and tolerability data, particularly for less frequent dosing (bimonthly/quarterly), or will efficacy tradeoffs emerge that temper its market potential and challenge the bullish outlook?
- Question 3
How will the FDA's request for voluntary withdrawal of Tavneos be resolved, and what will be the financial and reputational impact on Amgen Inc. in the near term?
Rerating Thresholds
| Metric | What'S Needed For Rerating | Why It Matters | Earnings Date |
|---|---|---|---|
| Biosimilar Portfolio Sales | Biosimilar Portfolio Sales growth falls below 10% year-over-year, or experiences a decline in absolute sales. | Amgen's biosimilar portfolio is a key growth driver and a source of durable cash flow, having grown 37% in 2025. A significant deceleration or decline in this segment would contradict the company's narrative of strong biosimilar pipeline performance and its ability to offset revenue erosion from its mature branded products, signaling weaker competitive strength and impacting future revenue and cash flow projections. | 2026-04-30 |
| Repatha Sales | Repatha sales growth for Q1 2026 needs to fall below 20% year-over-year. This would represent a significant deceleration from the 44% growth reported in Q4 2025 and the 36% full-year growth in 2025, challenging management's expectation for Repatha to be a key growth driver for the decade. | Repatha is a crucial growth driver for Amgen, essential for offsetting anticipated sales erosion from biosimilar competition for other products like Prolia and Otezla. A substantial slowdown in Repatha's growth would undermine the company's overall revenue momentum and its market leadership in cardiometabolic diseases, confirming a bearish outlook. | 2026-04-30 |
| Total Revenues | For a lower rerating (bearish confirmation), Amgen Inc. (AMGN) would need to report Q1 2026 total revenue growth below 3% year-over-year. This would fall short of the company's own guidance of 'lower mid-single-digit year-over-year growth' and the analyst consensus of 4.2% year-over-year growth for the quarter. | A total revenue growth below 3% year-over-year for Q1 2026 would signal that competitive pressures and biosimilar erosion for key products like Prolia and Otezla are exceeding management's and analysts' expectations. This would undermine the investment thesis that Amgen's diversified portfolio and promising pipeline can offset these declines, challenging its competitive position and potentially leading to downward revisions of full-year guidance and valuation. | 2026-04-30 |
Earnings Transcript Summary
· 2025Q4 Earnings Call
| 3 Things Management Is Most Focused On | Call Takeaway & Tone | Prior Quarter'S Y/Y Growth By Segment | 3 Things Analysts Most Pressed On (And Mgmt Responses) | Revenue Segments |
|---|---|---|---|---|
| 1. Driving growth from key products and pipeline: Management highlighted 14 products achieving blockbuster status, 13 with double-digit growth, and 18 achieving record results in 2025. They specifically called out Repatha, Evenity, and TestSpire as growing over 30% year-over-year and being "growth drivers not just for 2026, but for the rest of the decade." They also emphasized the rare disease, innovative oncology, and biosimilars portfolios. 2. Advancing a robust and differentiated pipeline, especially Meritide and opaziran: Management expressed strong confidence in Meritide for obesity, type 2 diabetes, and related conditions, emphasizing its potential for strong efficacy, favorable tolerability, and infrequent dosing (monthly, bimonthly, or quarterly). They also highlighted opaziran for elevated Lp(a) as an opportunity to expand leadership in cardiometabolic disease. 3. Disciplined execution, data generation, and financial discipline: Management repeatedly mentioned "strong disciplined execution across R&D" and "disciplined data generation" for 2026. Peter Griffith also underscored "rigorous management of working capital" and "maintaining rigorous financial discipline," while investing in the business and returning capital to shareholders. | The call conveyed a positive and confident tone. Management highlighted strong operational performance in 2025, with double-digit revenue and EPS growth, and expressed excitement about carrying this momentum into 2026. Key takeaways included the robust performance of established growth drivers (Repatha, Evenity, TestSpire), the significant potential of the late-stage pipeline, particularly Meritide for obesity and diabetes, and opaziran for cardiovascular disease, and the continued strength of their rare disease, innovative oncology, and biosimilars portfolios. Management emphasized disciplined execution, data generation, and financial rigor. While analysts pressed on competitive landscapes and pipeline specifics, management's responses consistently reinforced their strong market position, differentiated assets, and confidence in future growth. | Overall revenues: 12% year over year. Repatha: 40% year over year. EVENITY: 36% year over year. TEZSPIRE: 40% year over year. TEPEZZA: 15% year over year. UPLIZNA (EPLISMA): 46% year over year. TAVNEOS (TADNIA): 34% year over year. Biosimilar portfolio: 52% year over year. BLINCYTO: Double-digit growth (specific percentage not found). Prolia: No specific y/y growth percentage found for Q3 2025. Innovative oncology portfolio: Not explicitly stated as a combined segment, but Imdeltra had 33% sequential growth. Otezla: An intangible asset impairment charge of $400 million was recorded in Q3 2025, no y/y growth percentage found. Rare disease portfolio: Not explicitly stated as a combined segment, but individual rare disease products like Uplizna showed strong growth. | 1. Meritide's potential and dosing frequency (and the broader obesity portfolio): Analysts inquired about Amgen's overall obesity portfolio and the potential for Meritide's less frequent than monthly dosing. Management responded by emphasizing Meritide's potential as a "paradigm-changing therapy" with strong efficacy, good tolerability, and the ability to offer monthly, every eight-week, or quarterly dosing for maintenance, which they believe addresses a major unmet need and patient dissatisfaction with weekly GLP-1s. They also mentioned other clinical and preclinical assets in their obesity pipeline. 2. Aplisna's market opportunity and expansion into new indications (IgG4-related disease and gMG): Analysts asked about the size of the IgG4-related disease population and Aplisna's early uptake and role in the crowded generalized myasthenia gravis (gMG) market. Management acknowledged the evolving understanding of the IgG4-related disease epidemiology and expressed satisfaction with Aplisna's strong uptake across specialties. For gMG, they noted strong early interest from both bio-naive and switch patients, highlighting its upstream B-cell mechanism, safety profile, and twice-yearly dosing convenience as key differentiators. They also discussed the rationale for expanding Aplisna into autoimmune hepatitis and CIDP based on its mechanism. 3. Repatha's strategy amidst potential new PCSK9 competitors (like Merck's oral PCSK9): Analysts questioned how Amgen plans to maintain Repatha's leadership, especially with the potential launch of oral PCSK9 inhibitors, and the evolving role of primary care in prescribing. Management stressed the "landmark data" from the Vesalius CV trial, which demonstrated Repatha's ability to reduce the risk of first major cardiovascular events in high-risk primary and secondary prevention patients. They asserted that Repatha is the "most evidence-backed therapy in the PCSK9 class" and that new competitors "will not have the data package and profile that Repatha has established." They also noted that while primary prevention prescriptions were around 40%, they expect this to grow, with strong interest from both cardiologists and primary care physicians in the Vesalius data. | Overall sales growth: 10% year over year. Repatha sales: 36% year over year. Evenity sales: 34% year over year. Rare disease portfolio sales: 14% year over year (full year), 19% (Q4). EPLISMA sales: 73% year over year. TEPEZZA sales: 3% year over year. TADNIA sales: 62% year over year. TestBio (TESSPIRE) sales: 52% year over year. Otezla sales: 7% year over year. Innovative oncology portfolio sales: 11% year over year. BLINCYTO sales: 28% year over year. Biosimilar portfolio sales: 37% year over year. Prolia sales: 1% year over year. Imdeltro full-year sales: $627 million (y/y growth not specified). PAV Blue 2025 sales: $700 million (y/y growth not specified). |
Transcript Tidbits
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Broader Themes Emerging | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) | Hiring |
|---|---|---|---|---|---|---|---|---|
| Amgen Inc. sees significant growth opportunities by reaching new patients, expanding into additional geographies, and launching new indications for its rare disease portfolio. Repatha targets over 100 million people globally who still need effective LDL cholesterol lowering, with new data strengthening its position for both high-risk primary and secondary prevention, potentially leading to updated clinical guidelines. Evenity has a clear opportunity for growth as nearly 90% of the 2 million women at very high risk of fracture remain untreated. Uplisna received FDA approval for generalized myasthenia gravis and European Commission approval for IgG4-related disease in 2025, with strong early physician response and growing uptake across various specialties. Meritide is expanding its clinical landscape across obesity-related conditions, including two Phase III sleep apnea studies, and offers the potential for monthly, every other month, or even quarterly dosing. TEPEZZA plans to launch in additional international markets in 2026 and is expanding treatment to lower clinical activity score thyroid eye disease patients. Imdeltra is being advanced as combination therapy in frontline extensive-stage small cell lung cancer and in a Phase III study for limited-stage small cell lung cancer. | Amgen Inc. anticipates accelerated sales erosion for Prolia in 2026 due to increased competition from multiple biosimilars launched globally. Otezla is expected to face sales erosion from unfavorable pricing in the U.S. and generic launches, particularly in the EU. The company acknowledges anticipated declines from increased denosumab biosimilar competition and price declines for certain other products in 2026. Despite new entrants, Amgen Inc. asserts that Repatha will maintain its leadership due to its established data package and profile, which competitors will not have. Meritide is highlighted as standing alone in late-stage development for obesity and type two diabetes, offering strong efficacy and favorable tolerability at less frequent dosing compared to dozens of potential daily oral and weekly injectable medicines. Amgen Inc.'s biosimilars portfolio, which generated $3 billion in sales in 2025, is poised for growth with the next wave of launches, including ABP-206 (Opdivo biosimilar) and ABP-234 (Keytruda biosimilar). PAV Blue, a biosimilar to EYLEA, continues to gain momentum and is competing effectively against the innovator and anticipated future entrants. | The broader industry is experiencing a significant trend in the 'convergence of technology and life science,' which Amgen Inc. believes will have a substantial impact on how medicines are discovered, developed, and commercialized. Amgen Inc. is leveraging AI across its value chain to accelerate therapeutic discovery and late-stage development, optimize manufacturing, and improve customer engagement, driving productivity at speed and scale. | Amgen Inc. expects 2026 to be a 'springboard year for future growth,' with anticipated total revenues in the range of $37 billion to $38.4 billion and non-GAAP earnings per share between $21.6 to $23. The company highlights six areas of momentum for 2026, including Repatha, Evenity, and TestSpire, which are expected to be growth drivers for the rest of the decade. Amgen Inc. plans for 2026 to be a year of disciplined data generation from exciting Phase II and Phase III programs. The combination of Repatha, opaziran, and Meritide is seen as a compelling set of cardiometabolic medicines to expand leadership in serious chronic diseases well into the next decade. The company remains focused on delivering sustained long-term growth and creating value for patients and shareholders by advancing innovation in areas of high unmet medical need and maintaining rigorous financial discipline. | GLP1 | The 'convergence of technology and life science' is a broader theme emerging, with Amgen Inc. actively 'leveraging AI across the value chain to accelerate therapeutic discovery and late-stage development, optimize manufacturing, and improve customer engagement.' | Amgen Inc. delivered strong operational performance across the board in 2025. 14 of our products achieved blockbuster status with sales of a billion dollars or more. The strength of that broad portfolio enabled us to post double-digit growth in revenues and earnings per share for 2025. Meritide stands alone as the only therapy in late-stage development to offer the paradigm-changing prospect of strong efficacy and favorable tolerability at monthly, every other month, or even quarterly dosing. We expect our 2026 total revenues in the range of $37 billion to $38.4 billion and non-GAAP earnings per share between $21.6 to $23. positioning 2026 as a springboard year for future growth. | In 2026, we expect accelerated sales erosion driven by increased competition as multiple biosimilars have launched globally. For 2026, We expect sales erosion driven by unfavorable pricing in The U.S., and generic launches particularly in The EU. We recently announced the decision to terminate the role rocotinlimab development and commercialization collaboration with Kewa Kirin. We have decided not to pursue regulatory approval for bimirtuzumab. The FDA requested a voluntary withdrawal on January 16. We were surprised by this. |
Notes
| Date | Comment | Comment Type | Comment Sentiment | Link | IS CHANGE | Price Reaction |
|---|---|---|---|---|---|---|
| 2026-02-03 | Amgen reported strong Q4 2025 results with double-digit revenue and EPS growth, fueled by key products and an optimistic 2026 outlook. The company highlighted pipeline momentum, particularly for Meritide in obesity. Despite biosimilar competition and a Tavneos withdrawal request, the market reacted very positively, with the stock gaining 13.51% (t+2 days), significantly outperforming the SPY. | Earnings Transcript | Mixed | False | +13.51% (vs SPY: +13.35%) |
Upcoming Events
| Catalyst ID | Estimated Timing | Estimated Date Start | Estimated Date End | Catalyst | Why It Matters | Ticker Or Theme Specific | Transcript Date | Source Type |
|---|---|---|---|---|---|---|---|---|
| AMGN_a4f12076 | 2026 will be a year of disciplined data generation. From a number of exciting phase II and phase III programs that will pave the way for long-term growth at Amgen Inc. | 2026-01-01 | 2026-12-31 | Data generation and potential readouts from multiple ongoing Phase III clinical trials for Meritide in chronic weight management, ASCVD, heart failure, and sleep apnea. | Positive data from these late-stage trials could significantly enhance Amgen's competitive position in the rapidly expanding obesity and cardiometabolic markets, materially impacting future revenue guidance and valuation. Conversely, unfavorable outcomes would represent a significant setback. | Ticker | 2026-02-03 | earnings_transcript |
| AMGN_f22b3322 | As the study matures, we will update on the date for primary analysis as appropriate. | 2026-04-24 | 2026-12-31 | Update on the date for primary analysis of the fully enrolled OCEAN A outcome study for opaziran, an siRNA medicine targeting Lp(a) to reduce cardiovascular risk. | This update will establish the timeline for pivotal data availability for a potential best-in-class therapy in cardiovascular disease, influencing investor sentiment and future valuation. | Ticker | 2026-02-03 | earnings_transcript |
| AMGN_c80d6f15 | we expect to initiate two pivotal studies this year. | 2026-01-01 | 2026-12-31 | Initiation of two pivotal (Phase III) studies for Amgen's B cell depletion therapy in autoimmune hepatitis and chronic inflammatory demyelinating polyneuropathy (CIDP). | These initiations signify the advancement of new potential indications for Amgen's rare disease portfolio, expanding its market opportunity and future revenue streams. | Ticker | 2026-02-03 | earnings_transcript |
| AMGN_17b91ee0 | study completion expected in 2026. | 2026-07-01 | 2026-12-31 | Completion of both Phase III studies for desodoliveb, a CD40 ligand targeting biotherapeutic, in Sjogren's disease. | Study completion is a critical step before data readout and potential regulatory filings, which could position desodoliveb as a significant treatment option in a challenging autoimmune condition. | Ticker | 2026-02-03 | earnings_transcript |
| AMGN_1327efce | we expect study completion in the second half of this year. | 2026-07-01 | 2026-12-31 | Completion of Phase III studies for TestSpire in chronic obstructive pulmonary disease (COPD) and eosinophilic esophagitis. | Successful completion and subsequent positive data could lead to expanded indications for TestSpire, significantly increasing its market potential and revenue. | Ticker | 2026-02-03 | earnings_transcript |
| AMGN_fe4d51bf | We will update you on those discussions as necessary. | 2026-04-24 | 2026-12-31 | Resolution of ongoing discussions with the FDA regarding TABNIO's (avacopan) following a voluntary withdrawal request related to primary endpoint result readjudication. | The outcome will determine the future commercial viability of TABNIO's, impacting Amgen's rare disease portfolio and potentially leading to a re-evaluation of the product's sales trajectory. | Ticker | 2026-02-03 | earnings_transcript |
| AMGN_f1821dd7 | We plan to launch TEPEZZA in additional markets in 2026 | 2026-01-01 | 2026-12-31 | Launch of TEPEZZA in additional international markets. | Expanding TEPEZZA's geographic reach will contribute to its global sales growth and further establish Amgen's presence in the thyroid eye disease market. | Ticker | 2026-02-03 | earnings_transcript |
| AMGN_ce3d8cd2 | Including preparing for Miratide's launch. | 2026-01-01 | 2026-12-31 | Preparations and potential launch of Meritide, a novel therapy for obesity, type 2 diabetes, and related conditions. | Meritide is a key growth driver for Amgen. Its successful launch and market penetration would significantly impact Amgen's revenue and competitive position in the rapidly growing GLP-1 market. | Ticker | 2026-02-03 | earnings_transcript |